RxDoctor Payments Data

Anthony Malvasi, DO

Family Medicine · East Syracuse, NYNPI 1730443003

Payments from drug & device makers

$13,524in general payments, 2019–2025

Across 941 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$945
  • Pfizer$903
  • Teva Pharmaceuticals USA, Inc.$782
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$13,36099%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)143$1,950
AstraZeneca30$1,045
Lilly USA, LLC79$1,009
Amgen61$945
Pfizer76$903
Teva Pharmaceuticals USA, Inc.82$782
GSK68$698
Amarin Pharma, Inc.55$625
Astellas Pharma US Inc31$614
Bayer29$530
Novo Nordisk32$476
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$423
Takeda Pharmaceuticals U.S.A., Inc.28$353
Biohaven Pharmaceuticals, Inc.27$295
Johnson & Johnson12$278
Novartis15$275
Exact Sciences15$245
Biohaven Pharmaceutical Holding Company Ltd.32$235
Daiichi Sankyo Inc.8$191
Boehringer Ingelheim11$177
Merck9$137
Eisai Inc.4$95
Sanofi-aventis U.S. LLC4$92
Insulet Corporation5$92
Sumitomo Pharma America, Inc.1$78
UCB, Inc.3$68
Esperion Therapeutics, Inc.4$68
Shield Therapeutics Inc3$60
Otsuka America Pharmaceutical, Inc.3$57
Corium, LLC6$55
Kowa Pharmaceuticals America, Inc.4$46
Dexcom, Inc.2$41
Almatica Pharma LLC2$36
Boston Scientific1$35
Mannkind Corporation2$34
Genentech USA, Inc.2$34
Gilead2$33
Ironwood Pharmaceuticals, Inc2$33
Arbor Pharmaceuticals, Inc.2$32
Madrigal Pharmaceuticals1$28
Collegium Pharmaceutical, Inc.2$28
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$26
Philips North America LLC1$25
Abbott1$22
Phathom Pharmaceuticals, Inc.3$21
Medicomp Inc1$18
E.r. Squibb & Sons, L.L.C.1$17
Idorsia Pharmaceuticals US Inc1$16
Neurocrine Biosciences, Inc.1$16
Regeneron Healthcare Solutions, Inc.1$16
IBSA Pharma Inc.1$15
Amneal Pharmaceuticals LLC1$15
Bristol Myers Squibb1$14
Vertex1$14
Biogen1$14
Paratek Pharmaceuticals, Inc.1$13
Nestle Healthcare Nutrition Inc.1$13
Cequr Corporation1$13
Neuronetics, Inc.1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,524 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$90,916
Medicare patients
247
Services billed
2,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$63,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$54,916
FarxigaDapagliflozin Propanediol34$53,499
JardianceEmpagliflozin30$28,577
JanuviaSitagliptin Phosphate16$26,132
MounjaroTirzepatide18$23,815
ProliaDenosumab14$23,603
XareltoRivaroxaban15$22,623
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$21,777
EliquisApixaban17$20,006
Repatha SureclickEvolocumab11$17,262
UbrelvyUbrogepant14$13,746
TrulicityDulaglutide11$12,216
KerendiaFinerenone12$11,510
BelbucaBuprenorphine Hcl11$10,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$698$64,06281 claims
Novo NordiskOzempic$476$63,75932 claims
AstraZenecaFarxiga$1,045$53,49934 claims
Lilly USA, LLCMounjaro, Trulicity$1,009$36,03129 claims
MerckJanuvia, Belsomra$137$33,03932 claims
Boehringer IngelheimJardiance$177$28,57730 claims
PfizerEliquis, Paxlovid$903$24,12631 claims
AmgenProlia$945$23,60314 claims
Johnson & JohnsonXarelto$278$22,62315 claims
AbbVieUbrelvy$1,950$13,74614 claims
BayerKerendia$530$11,51012 claims
Collegium Pharmaceutical, Inc.Belbuca$28$10,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →